Summary
A Phase III double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of Drug A in patients with moderate to severe chronic back pain.
Register to download
Succeeding with a Risk-Based Approach
You may also be interested in:
Fact Sheet
CSF Sampling
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…
View Resource
Newsletter
RARE DISEASES NEWSLETTER Volume 17, July 2020
Welcome to the seventeenth edition of the rare disease newsletter. A few months has changed the world of clinical research into a very different…
View Resource
Blog
HEALEY ALS Platform Trial Drives Innovation in ALS Clinical Research
Amyotrophic lateral sclerosis (ALS) is a lethal, relentlessly progressive neurodegenerative disease, and the most common adult-onset motor neuron…
Read Story
View all related content and resources for Study Design
Explore Insights